Sartorius Stedim Biotech Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 10,483

Employees

  • Stock Symbol
  • DIM

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $250.80
  • (As of Thursday Closing)

Sartorius Stedim Biotech General Information

Description

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.

Contact Information

Formerly Known As
Stedim
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Zone Industrielle les Paluds
  • Avenue de Jouques CS 91051
  • 13781 Aubagne
  • France
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Commercial Products
Industrial Supplies and Parts
Stock Exchange
PAR
Corporate Office
  • Zone Industrielle les Paluds
  • Avenue de Jouques CS 91051
  • 13781 Aubagne
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sartorius Stedim Biotech Stock Performance

As of 19-Nov-2026, Sartorius Stedim Biotech’s stock price is $250.80. Its current market cap is $24.4B with 97.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$250.80 $249.31 $175.26 - $262.41 $24.4B 97.3M 91.9K $3.87

Sartorius Stedim Biotech Financials Summary

As of 30-Sep-2026, Sartorius Stedim Biotech has a trailing 12-month revenue of $3.56B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 25,983,244 26,655,690 21,567,642 28,528,719
Revenue 3,556,914 3,347,358 3,008,235 3,003,300
EBITDA 1,018,369 924,063 705,096 811,016
Net Income 376,326 299,598 189,476 335,768
Total Assets 9,115,919 9,378,157 8,591,378 8,544,852
Total Debt 2,620,036 3,053,187 2,986,025 4,070,082
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sartorius Stedim Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sartorius Stedim Biotech‘s full profile, request access.

Request a free trial

Sartorius Stedim Biotech Patents

Sartorius Stedim Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240209411-A1 Method for sterility testing Pending 26-Apr-2021
US-10947489-B2 Bioreactor system and method Active 02-Jun-2015
US-20180187140-A1 Bioreactor system and method Active 02-Jun-2015
WO-2013160594-A1 Sterile individual set for producing biopharmaceutical products Inactive 24-Apr-2012
WO-2013102738-A1 Container for biopharmaceutical content Inactive 05-Jan-2012 C12M29/00
To view Sartorius Stedim Biotech’s complete patent history, request access »

Sartorius Stedim Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sartorius Stedim Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sartorius Stedim Biotech‘s full profile, request access.

Request a free trial

Sartorius Stedim Biotech Investments & Acquisitions (14)

Sartorius Stedim Biotech’s most recent deal was a Later Stage VC with Nanotein Technologies for . The deal was made on 11-Aug-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nanotein Technologies 11-Aug-2025 Later Stage VC Drug Discovery
ViroCell Biologics 14-Aug-2024 Early Stage VC Other Pharmaceuticals and Biotechnology
ViroCell Biologics 15-Nov-2022 Early Stage VC Other Pharmaceuticals and Biotechnology
Xell 29-Jul-2021 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Novasep (Chromatography Equipment Division) 07-Feb-2021 Merger/Acquisition Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Sartorius Stedim Biotech ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

18.96 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Sartorius Stedim Biotech’s complete esg history, request access »

Sartorius Stedim Biotech Exits (2)

Sartorius Stedim Biotech’s most recent exit was on 14-Aug-2024 from ViroCell Biologics. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
ViroCell Biologics 14-Aug-2024 Completed
  • 3 buyers
ViroCell Biologics 15-Nov-2022 Early Stage VC Completed
  • 2 buyers
To view Sartorius Stedim Biotech’s complete exits history, request access »

Sartorius Stedim Biotech Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Sartorius Chromatography Equipment Pompey, France 2020
Sartorius Stedim Fmt Aubagne, France 2012
Xell Schloß Holte-Stukenbrock, Germany 2009
Sartorius Stedim Aseptics Lourdes, France 1994

Sartorius Stedim Biotech FAQs

  • When was Sartorius Stedim Biotech founded?

    Sartorius Stedim Biotech was founded in 1978.

  • Where is Sartorius Stedim Biotech headquartered?

    Sartorius Stedim Biotech is headquartered in Aubagne, France.

  • What is the size of Sartorius Stedim Biotech?

    Sartorius Stedim Biotech has 10,483 total employees.

  • What industry is Sartorius Stedim Biotech in?

    Sartorius Stedim Biotech’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Sartorius Stedim Biotech a private or public company?

    Sartorius Stedim Biotech is a Public company.

  • What is Sartorius Stedim Biotech’s stock symbol?

    The ticker symbol for Sartorius Stedim Biotech is DIM.

  • What is the current stock price of Sartorius Stedim Biotech?

    As of 19-Nov-2026 the stock price of Sartorius Stedim Biotech is $250.80.

  • What is the current market cap of Sartorius Stedim Biotech?

    The current market capitalization of Sartorius Stedim Biotech is $24.4B.

  • What is Sartorius Stedim Biotech’s current revenue?

    The trailing twelve month revenue for Sartorius Stedim Biotech is $3.56B.

  • What is Sartorius Stedim Biotech’s annual earnings per share (EPS)?

    Sartorius Stedim Biotech’s EPS for 12 months was $3.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process